Immunity Induced by Vaccination with Recombinant Influenza B Virus Neuraminidase Protein Breaks Viral Transmission Chains in Guinea Pigs in an Exposure Intensity-dependent Manner

Overview

Journal bioRxiv

Date 2022 Oct 27

PMID 36299418

Authors

Meagan McMahon

Jessica Tan

George ODell

Ericka Kirkpatrick Roubidoux

Shirin Strohmeier

Florian Krammer

Affiliations

Soon will be listed here.

Abstract

Mucosal vaccines and vaccines that block pathogen transmission are under-appreciated in vaccine development. However, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has shown that blocking viral transmission is an important attribute of efficient vaccines. Here, we investigated if recombinant influenza virus neuraminidase (NA) vaccines delivered at a mucosal site could protect from onward transmission of influenza B viruses in the guinea pig model. We tested four different scenarios in which sequential transmission was investigated in chains of four guinea pigs. The variables tested included a low and a high viral inoculum (10 vs 10 plaque forming units) in the initial donor guinea pig and variation of exposure/cohousing time (1 day vs 6 days). In three out of four scenarios - low inoculum-long exposure, low inoculum-short exposure and high inoculum-short exposure - transmission chains were efficiently blocked. Based on this data we believe an intranasal recombinant NA vaccine could be used to efficiently curtail influenza virus spread in the human population during influenza epidemics.

References

Palese P, Compans R . Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol. 1976; 33(1):159-63. DOI: 10.1099/0022-1317-33-1-159. View

McMahon M, Kirkpatrick E, Stadlbauer D, Strohmeier S, Bouvier N, Krammer F . Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs. mBio. 2019; 10(3). PMC: 6529633. DOI: 10.1128/mBio.00560-19. View

Frise R, Bradley K, van Doremalen N, Galiano M, Elderfield R, Stilwell P . Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. Sci Rep. 2016; 6:29793. PMC: 4949428. DOI: 10.1038/srep29793. View

Krammer F, Fouchier R, Eichelberger M, Webby R, Shaw-Saliba K, Wan H . NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?. mBio. 2018; 9(2). PMC: 5885027. DOI: 10.1128/mBio.02332-17. View

Cohen M, Zhang X, Senaati H, Chen H, Varki N, Schooley R . Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J. 2013; 10:321. PMC: 3842836. DOI: 10.1186/1743-422X-10-321. View

Xu X, Zhu X, Dwek R, Stevens J, Wilson I . Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol. 2008; 82(21):10493-501. PMC: 2573172. DOI: 10.1128/JVI.00959-08. View

Strohmeier S, Amanat F, Zhu X, McMahon M, Deming M, Pasetti M . A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. mBio. 2021; 12(6):e0224121. PMC: 8609353. DOI: 10.1128/mBio.02241-21. View

Krammer F, Margine I, Tan G, Pica N, Krause J, Palese P . A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One. 2012; 7(8):e43603. PMC: 3426533. DOI: 10.1371/journal.pone.0043603. View

Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D . Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2021; 75:103788. PMC: 8718969. DOI: 10.1016/j.ebiom.2021.103788. View

10.

Wohlbold T, Krammer F . In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses. 2014; 6(6):2465-94. PMC: 4074938. DOI: 10.3390/v6062465. View

11.

McAuley J, Gilbertson B, Trifkovic S, Brown L, McKimm-Breschkin J . Influenza Virus Neuraminidase Structure and Functions. Front Microbiol. 2019; 10:39. PMC: 6362415. DOI: 10.3389/fmicb.2019.00039. View

12.

Strohmeier S, Carreno J, Brito R, Krammer F . Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice. Vaccines (Basel). 2021; 9(4). PMC: 8072926. DOI: 10.3390/vaccines9040404. View

13.

Liu W, Lin C, Tsou Y, Jan J, Wu S . Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. J Virol. 2015; 89(14):7224-34. PMC: 4473581. DOI: 10.1128/JVI.00585-15. View

14.

Javaid W, Ehni J, Gonzalez-Reiche A, Carreno J, Hirsch E, Tan J . Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology. Clin Infect Dis. 2020; 73(11):e4375-e4383. PMC: 8653627. DOI: 10.1093/cid/ciaa1781. View

15.

KILBOURNE E, Johansson B, Grajower B . Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A. 1990; 87(2):786-90. PMC: 53351. DOI: 10.1073/pnas.87.2.786. View

16.

Deroo T, Jou W, Fiers W . Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine. 1996; 14(6):561-9. DOI: 10.1016/0264-410x(95)00157-v. View

17.

Margine I, Palese P, Krammer F . Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp. 2013; (81):e51112. PMC: 3970794. DOI: 10.3791/51112. View

18.

Lowen A, Mubareka S, Tumpey T, Garcia-Sastre A, Palese P . The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A. 2006; 103(26):9988-92. PMC: 1502566. DOI: 10.1073/pnas.0604157103. View

19.

Kawai A, Yamamoto Y, Nogimori T, Takeshita K, Yamamoto T, Yoshioka Y . The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses. J Virol. 2021; 95(20):e0118021. PMC: 8475506. DOI: 10.1128/JVI.01180-21. View

20.

Strohmeier S, Amanat F, Campbell J, Traquina P, Coffman R, Krammer F . A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccines. 2022; 7(1):81. PMC: 9305062. DOI: 10.1038/s41541-022-00486-w. View